Weight Gain Mitigation with Topiramate in Mood Disorders

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 887-891

  Woods, Tonja M ^a,d   Eichner, Samantha F ^b,c   Franks, Andrea S ^c  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF WYOMING   (United States)

Author keywords

Bipolar disorder; Mood disorder; Topiramate; Weight loss

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; LITHIUM; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROIC ACID; ZUCLOPENTHIXOL ACETATE;

ANXIETY DISORDER; APPETITE DISORDER; BIPOLAR DISORDER; BODY MASS; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; GASTROINTESTINAL DISEASE; HUMAN; MAJOR DEPRESSION; MANIA; MONOTHERAPY; MOOD DISORDER; PARESTHESIA; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; REVIEW; SOMNOLENCE; TITRIMETRY; VISUAL IMPAIRMENT; WEIGHT GAIN;

ANTICONVULSANTS; CLINICAL TRIALS; FRUCTOSE; HUMANS; MOOD DISORDERS; WEIGHT LOSS;

EID: 1942470592     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D219     Document Type: Review

References (25)

1. Malhotra S, McElroy SL. Medical management of obesity associated with mental disorders. J Clin Psychiatry 2002;63(suppl 4):24-32.
2. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000;61:179-84.
3. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31.
4. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003;160:112-7.
5. Colditz GA, Willet WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122:481-6.
6. Teter CJ, Early JJ, Gibbs CM. Treatment of affective disorder and obesity with topiramate. Ann Pharmacother 2000;34:1262-4. DOI 10.1345/aph. 10027
7. Package insert. Topamax (topiramate). Raritan, NJ: McNeil Pharmaceuticals, May 2002.
8. Li X, Ketter TA, Frye MA. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disorders 2002;69:1-14.
9. Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998;804:169-76.
10. Shapiro NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61: 368-72.
11. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 2002;47:271-3.
12. Richard D, Ferland J, Lalone J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16:961-6.
13. Dursan SM, Devarajan S. Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? Can J Psychiatry 2001;46:287-8.
14. Brown RO, Orr CD, Hanna DL, Williams JE, Dickerson RN. Topiramate and weight loss in patients with neurodevelopment disabilities. Pharmacotherapy 2002;22:831-5.
15. Gupta S, Masand PS, Frank BL, Lockwood KL, Keller PL. Topiramate in bipolar and schizoaffective disorders: weight loss and efficacy. J Clin Psychiatry 2000;2:96-100.
16. Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999;156:968-9.
17. Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain (letter). J Am Acad Child Adolesc Psychiatry 2001;40:12.
18. Colom F, Vieta E, Benabarre A, Martinez-Aran A, Reinares M, Corbella B, et al. Topiramate abuse in a bipolar patient with an eating disorder. J Clin Psychiatry 2001;16:167-72.
19. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025-33.
20. Bozikas VP, Petrikis P, Kourtis A, Youlis P, Karavatos A. Treatment of acute mania with topiramate in hospitalized patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1203-6.
21. Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J Clin Psychiatry 2002;63:981-4.
22. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1035-9.
23. Ghaemi SN, Manwani SG, Katzow JJ, Ko JY, Goodwin FK. Topiramte treatment of bipolar spectrum disorders: a retrospective chart review. Ann Clin Psychiatry 2001;13:185-9.
24. Chengappa KNR, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized, chart review. Clin Ther 2002;24:1576-84.
25. Carpenter L, Leon Z, Yasmin S, Price LH. Do obese patients respond to topiramate? A retrospective chart review. J Affect Disord 2002;69:251-5.